These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 34986506)

  • 1. Determining the minimal important differences in the RQLQ score with grass and tree allergy immunotherapy versus placebo in adults with moderate-to-severe allergy.
    Blaiss MS; Gronskyte Juhl R; Siew LQC; Hammerby E; Devillier P
    Allergy; 2022 Jun; 77(6):1843-1851. PubMed ID: 34986506
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sublingual Tablet Immunotherapy Improves Quality of Life in Adults With Allergic Rhinoconjunctivitis.
    Blaiss MS; Durham SR; Bernstein D; Stranzl T; Lindholm M; Nolte H; Andersen KF; Roberts G
    J Allergy Clin Immunol Pract; 2024 Jun; 12(6):1520-1529.e5. PubMed ID: 38307205
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunotherapy With the SQ Tree SLIT-tablet in Adults and Adolescents With Allergic Rhinoconjunctivitis.
    Mäkelä MJ; Gyllfors P; Valovirta E; Steffensen MA; Grønager PM; Savolainen J; Winther L
    Clin Ther; 2018 Apr; 40(4):574-586.e4. PubMed ID: 29551533
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sustained effect of SQ-standardized grass allergy immunotherapy tablet on rhinoconjunctivitis quality of life.
    Frølund L; Durham SR; Calderon M; Emminger W; Andersen JS; Rask P; Dahl R
    Allergy; 2010 Jun; 65(6):753-7. PubMed ID: 19886920
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SQ grass sublingual allergy immunotherapy tablet for disease-modifying treatment of grass pollen allergic rhinoconjunctivitis.
    Dahl R; Roberts G; de Blic J; Canonica GW; Kleine-Tebbe J; Nolte H; Lawton S; Nelson HS
    Allergy Asthma Proc; 2016; 37(2):92-104. PubMed ID: 26802643
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment Effect of the Tree Pollen SLIT-Tablet on Allergic Rhinoconjunctivitis During Oak Pollen Season.
    Nolte H; Waserman S; Ellis AK; Biedermann T; Würtzen PA
    J Allergy Clin Immunol Pract; 2021 May; 9(5):1871-1878. PubMed ID: 33548518
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Once-daily sublingual allergen-specific immunotherapy improves quality of life in patients with grass pollen-induced allergic rhinoconjunctivitis: a double-blind, randomised study.
    Rak S; Yang WH; Pedersen MR; Durham SR
    Qual Life Res; 2007 Mar; 16(2):191-201. PubMed ID: 17033900
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sublingual allergen immunotherapy with a liquid birch pollen product in patients with seasonal allergic rhinoconjunctivitis with or without asthma.
    Pfaar O; Bachert C; Kuna P; Panzner P; Džupinová M; Klimek L; van Nimwegen MJ; Boot JD; Yu D; Opstelten DJE; de Kam PJ
    J Allergy Clin Immunol; 2019 Mar; 143(3):970-977. PubMed ID: 30508538
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunologic effects and tolerability profile of in-season initiation of a standardized-quality grass allergy immunotherapy tablet: a phase III, multicenter, randomized, double-blind, placebo-controlled trial in adults with grass pollen-induced rhinoconjunctivitis.
    Reich K; Gessner C; Kroker A; Schwab JA; Pohl W; Villesen H; Wüstenberg E; Emminger W
    Clin Ther; 2011 Jul; 33(7):828-40. PubMed ID: 21741092
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 300IR 5-Grass pollen sublingual tablet offers relief from nasal symptoms in patients with allergic rhinitis.
    Serrano E; Wahn HU; Didier A; Bachert C
    Am J Rhinol Allergy; 2014; 28(6):471-6. PubMed ID: 25335122
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase 3 trial assessing the efficacy and safety of grass allergy immunotherapy tablet in subjects with grass pollen-induced allergic rhinitis with or without conjunctivitis, with or without asthma.
    Murphy K; Gawchik S; Bernstein D; Andersen J; Pedersen MR
    J Negat Results Biomed; 2013 Jun; 12():10. PubMed ID: 23725348
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A quality-of-life mapping function developed from a grass pollen sublingual immunotherapy trial to a tree pollen sublingual immunotherapy trial.
    Dick K; Briggs A; Ohsfeldt R; Sydendal Grand T; Buchs S
    J Med Econ; 2020 Jan; 23(1):64-69. PubMed ID: 31352853
    [No Abstract]   [Full Text] [Related]  

  • 13. Sublingual immunotherapy tablets in monosensitized and polysensitized adults with allergic rhinoconjunctivitis.
    Nelson HS; Bernstein DI; Biedermann T; Nolte H
    Allergy Asthma Proc; 2024 Jan; 45(1):33-36. PubMed ID: 38151733
    [No Abstract]   [Full Text] [Related]  

  • 14. The SQ tree SLIT-tablet is highly effective and well tolerated: Results from a randomized, double-blind, placebo-controlled phase III trial.
    Biedermann T; Kuna P; Panzner P; Valovirta E; Andersson M; de Blay F; Thrane D; Jacobsen SH; Stage BS; Winther L
    J Allergy Clin Immunol; 2019 Mar; 143(3):1058-1066.e6. PubMed ID: 30654054
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lack of effect of Timothy grass pollen sublingual immunotherapy tablet on birch pollen-induced allergic rhinoconjunctivitis in an environmental exposure unit.
    Ellis AK; Tenn MW; Steacy LM; Adams DE; Day AG; Walker TJ; Nolte H
    Ann Allergy Asthma Immunol; 2018 May; 120(5):495-503.e2. PubMed ID: 29432967
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis.
    Durham SR; Yang WH; Pedersen MR; Johansen N; Rak S
    J Allergy Clin Immunol; 2006 Apr; 117(4):802-9. PubMed ID: 16630937
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Post-treatment efficacy of discontinuous treatment with 300IR 5-grass pollen sublingual tablet in adults with grass pollen-induced allergic rhinoconjunctivitis.
    Didier A; Malling HJ; Worm M; Horak F; Sussman G; Melac M; Soulié S; Zeldin RK
    Clin Exp Allergy; 2013 May; 43(5):568-77. PubMed ID: 23600548
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Conjunctival provocation tests: a predictive factor for patients' seasonal allergic rhinoconjunctivitis symptoms.
    Kruse K; Gerwin E; Eichel A; Shah-Hosseini K; Mösges R
    J Allergy Clin Immunol Pract; 2015; 3(3):381-6. PubMed ID: 25609338
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RCAT reflects symptom control and quality of life in allergic rhinoconjunctivitis patients.
    Liedtke JP; Mandl A; Köther J; Chwieralski J; Shah-Hosseini K; Raskopf E; Pieper-Fürst U; Allekotte S; Mösges R
    Allergy; 2018 May; 73(5):1101-1109. PubMed ID: 29159975
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The relevance of patient-reported outcomes in a grass pollen immunotherapy trial in children and adolescents with rhinoconjunctivitis.
    Röder E; Berger MY; Hop WC; de Groot H; van Wijk RG
    Pediatr Allergy Immunol; 2013 Feb; 24(1):39-48. PubMed ID: 22882319
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.